The groundbreaking success of Sildenafil undeniably revolutionized the pharmaceutical landscape, but placing funds in companies strongly reliant on off-patent versions presents a uncertain picture. Despite early earnings were substantial, the cessation of patents and the rise of discounted alternatives have diminished the customer base. Thus, a tho